SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Bill Wexler's Profits of DOOM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (565)4/8/1998 5:04:00 PM
From: Biojunkie  Read Replies (1) of 4634
 
Ever since this stock made its move up on heavy volume, I have looked into this company's science. What is interesting to me, is the difference between the perception and the reality. The perception is that their product is DHEA as an antiretroviral. This is further confused by the fact that some form of DHEA is sold in health food stores as a dietary supplement. Unfortunately, this DHEA is generally not bioavailable. Upon further investigation, there were studies conducted in the late 80's and early 90's that confirmed bioavailable DHEA's correlation with an antiretroviral effect. This was before the DISHA act of 1994 that enabled stores to sell the non-bioavailable form of DHEA.

All that said, the reality is what HEPH describes in their latest public filings and releases is that their lead compound "Inactivin" is an analogue (PPB2) of the hormonal family of DHEA, and is ten times more potent than the bioavailable form of DHEA (which showed a 90% reduction in viral load, in a clinical study). Clearly, if the latest generation of "Inactivin" i.e. the analogue or "PPB2" is ten times more potent, one could expect a magnitude greater viral load reduction than the 90% seen in bioavailable DHEA. Add in the lack of resistance to multi-drug resistant strains, lack of toxicity and side effect profile, its simple regimen and relatively low cost purported by the company...sounds like it might be worthy of further analysis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News